Tesamorelin 5mg
A stabilized GHRH analog investigated for physiological growth hormone stimulation and targeted reduction of visceral abdominal adipose tissue.
Mechanism
Binds pituitary GHRH receptors to stimulate physiological, pulsatile release of endogenous growth hormone and elevate systemic IGF-1 levels.
Dosing
Standard laboratory protocols evaluate a starting baseline of 2 mg (2000 mcg) administered subcutaneously once per day, optionally preceded by a 1 mg introductory phase.
Reconstitution
Reconstitute with 2.5 mL of bacteriostatic water to achieve a final working concentration of 2.0 mg/mL (2,000 mcg/mL).
Storage
Store unmixed lyophilized vials refrigerated at 2–8 °C; after reconstitution, maintain at 2–8 °C and avoid freezing.
Mix & measure Tesamorelin 5mg
Pre-filled with this protocol's recommended BAC water and documented starting dose — edit any field to run your own numbers.
Mix & measure Tesamorelin 5mg
Vial strength → BAC water → target dose
Common vial sizes
Label claim
Total doses in vial: 2.5
U-100 syringe: 100 units = 1 mL
Need supplies for this protocol?
Research-grade peptides, fast shipping, competitive pricing
Reconstitution math only — not dosing advice. U-100 syringe: 100 units = 1 mL. Advanced calculator →
Track my protocol
Log each dose, build a streak, and watch your progress through this protocol's schedule.
Dosing Chart
| Phase / Day(s) | Dose & Frequency | Volume (U-100 units / mL) |
|---|---|---|
| Week 1 (optional titration) | 1 mg / 1000 mcg (1× daily) | 50 units (0.50 mL) |
| Weeks 2–12+ | 2 mg / 2000 mcg (1× daily) | 100 units (1.00 mL) |
Reconstitution Steps
- 1
Aseptically draw 2.5 mL of bacteriostatic water using a sterile syringe.
- 2
Introduce the diluent slowly down the interior glass wall of the 5 mg Tesamorelin vial to avoid excess agitation.
- 3
Gently swirl or roll the vial until the lyophilized powder is completely dissolved, taking care not to shake.
- 4
Inspect the clear liquid, label the vial with concentration and preparation date, and store under refrigeration at 2–8 °C.
Supplies Needed
Peptide Vial
Provides 5 mg of lyophilized Tesamorelin peptide cake for reconstitution.
Insulin Syringes (U-100)
Utilized for precise volumetric measurement and subcutaneous administration of doses.
Bacteriostatic Water
Acts as the sterile, preserved diluent (2.5 mL per vial) to reconstitute the peptide.
Alcohol Swabs
Used to disinfect the rubber vial stoppers and injection sites before handling.
Why researchers study it
Visceral fat reduction
Pulsatile GH and IGF-1 secretion
Hepatic lipid content in NAFLD models
Age-related cognitive function
These describe what is being studied, not proven benefits, approved uses, or promised results.
Overview
Tesamorelin is an engineered 44-amino-acid synthetic peptide that acts as an analog of native growth hormone-releasing hormone (GHRH). By incorporating a trans-3-hexenoic acid moiety, the peptide exhibits enhanced enzymatic stability compared to endogenous GHRH, allowing for prolonged biological activity. It selectively triggers GHRH receptors on pituitary somatotrophs, encouraging the natural, pulsatile secretion of endogenous growth hormone without fully overriding negative feedback mechanisms. In investigative and clinical contexts, the resulting rise in circulating insulin-like growth factor 1 (IGF-1) activates downstream lipolytic pathways, specifically targeting deep visceral adipose depots rather than superficial subcutaneous fat. While commercially developed and approved under brand formulations for HIV-associated lipodystrophy, academic research continues to explore its systemic metabolic impacts across broader models of lipid dysregulation and hepatic steatosis. Within laboratory research frameworks, the 5 mg vial format offers a standardized volume for testing endocrine signaling pathways. Standard handling requires precise reconstitution to preserve peptide integrity, followed by controlled administration schedules often timed to mirror natural nocturnal hormone rhythms.
References
- 1.FDA, Prescribing Information (Egrifta / Egrifta SV), — approved indication, dosing and storage
- 2.Mayo Clinic / IBM Merative, Drug Information, — mechanism, GH/IGF-1 stimulation, administration and timing
- 3.Falutz et al., J. Clin. Endocrinol. Metab., 2010 — pooled analysis of two phase 3 trials in HIV-infected patients with excess abdominal fat
- 4.Stanley et al., Lancet HIV, 2014 — safety and metabolic effects including visceral fat, lipids, and NAFLD
- 5.NIH/NIDDK, LiverTox Bookshelf, 2018 — formulation storage (Egrifta vs Egrifta SV) and reconstitution handling
- 6.NCBI Bookshelf, Egrifta Medication Guide, — adverse effects, contraindications, IGF-1 monitoring, and site rotation
- 7.CDC, Vaccine Administration Guidelines, — subcutaneous injection technique: angle, site, and no-aspiration guidance
- 8.University of Michigan Health, Clinical Guidelines, — patient education on subcutaneous injection technique
Supplies Needed
Suggested supplier
Research use only. Listing a supplier is not an endorsement of any protocol on this site, and nothing sold there is approved for human use.
Related protocols
View allTestoluten 20mg
An oral animal-derived testicular peptide extract explored in bioregulator research for male endocrine and reproductive support.
View ProtocolHumanin 5mg
Mitochondrial-derived peptide and potent HNG analog researched for cellular survival, metabolic signaling, and cytoprotective pathways.
View ProtocolSelank 5mg
Synthetic tuftsin-derived heptapeptide investigated for non-sedating anxiolysis, cognitive support, and neurotrophic modulation.
View Protocol